You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
G. F. Schecter, C. Scott, L. True, A. Raftery, J. Flood and S. Mase
Clinical Infectious Diseases
Vol. 50, No. 1 (1 January 2010), pp. 49-55
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/27799505
Page Count: 7
Preview not available
Background. Linezolid is a new antibiotic with activity against Mycobacterium tuberculosis in vitro and in animal studies. Several small case series suggest that linezolid is poorly tolerated because of the side effects of anemia/thrombocytopenia and peripheral neuropathy. To characterize our clinical experience with linezolid, the California Department of Public Health Tuberculosis Control Branch's Multidrug-Resistant Tuberculosis (MDR-TB) Service reviewed cases in which the MDR-TB treatment regimens included linezolid therapy. Methods. Record review was performed for 30 patients treated with linezolid as part of an MDR-TB regimen. Data were collected on clinical and microbiological characteristics, linezolid tolerability, and treatment outcomes. The dosage of linezolid was 600 mg daily. Vitamin B6 at a dosage of 50–100 mg daily was used to mitigate hematologic toxicity. Results. During 2003–2007, 30 patients received linezolid for the treatment of MDR-TB. Patients had isolates resistant to a median of 5 drugs (range, 2–13 drugs). Of the 30 cases, 29 (97%) were pulmonary; of these 29, 21 (72%) had positive results of acid-fast bacilli smear, and 16 (55%) were cavitary. Culture conversion occurred in all pulmonary cases at a median of 7 weeks. At data censure (31 December 2008), 22 (73%) of 30 patients had successfully completed treatment. Five continued to receive treatment. There were no deaths. Three patients had a poor outcome, including 2 defaults and 1 treatment failure. Side effects occurred in 9 patients, including peripheral and optic neuropathy, anemia/thrombocytopenia, rash, and diarrhea. However, only 3 patients stopped linezolid treatment because of side effects. Conclusions. Linezolid was well tolerated, had low rates of discontinuation, and may have efficacy in the treatment of MDR-TB.
Clinical Infectious Diseases © 2010 Oxford University Press